Novartis Sued Over Cancer Drug's Patent Validity

Law360, New York (June 11, 2013, 4:01 PM EDT) -- Novartis Pharmaceuticals Corp. was slapped with a suit in New Jersey federal court Friday by a Sun Pharmaceutical Industries Ltd. unit demanding that it be free to market a generic version of blockbuster cancer drug Gleevec prior to the expiration of a Novartis patent.

Sun Pharma Global FZE's suit seeks a declaratory judgment allowing the India-based generic drug manufacturer to start marketing tablet products containing the active ingredient imatinib mesylate — the same active ingredient as in Gleevec — before U.S. Patent Number 6,894,051 has expired....
To view the full article, register now.